

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claims 1-15. (Canceled)

16. (Currently Amended) A method of preventing conception in a female subject by modulating chorionic gonadotropin (CG) activity ~~reducing the incidence of pregnancy in a female subject~~ comprising administering to a female subject an amount of an agent effective at reducing the incidence of conception, wherein the agent comprises a peptide selected from the group consisting of:

- a) a peptide consisting of the ~~[[LHR<sup>exo1</sup>],]~~ human LHR<sup>exo2</sup> or LHR<sup>exo3</sup> domain, or any combination thereof;
- b) ~~a peptide about 24-32 residues in length and comprising the amino acid sequence of the LHR<sup>exo1</sup> domain or a sequence at least 95% identical to the amino acid sequence of the LHR<sup>exo1</sup> domain;~~
- c) a peptide about ~~21-29~~ 19-21 residues in length and comprising the amino acid sequence of the human LHR<sup>exo2</sup> domain or a sequence at least ~~[[95%]]~~ 85% identical to the amino acid sequence of the human LHR<sup>exo2</sup> domain; and
- d) a peptide about ~~12-20~~ 10-12 residues in length and comprising the amino acid sequence of the human LHR<sup>exo3</sup> domain or a sequence at least ~~[[95%]]~~ 91% identical to the amino acid sequence of the human LHR<sup>exo3</sup> domain,

wherein the peptide binds CG and inhibits CG interaction with the ~~[[exoloop 1,]]~~ exoloop 2 or exoloop 3 domain of the LHR.

Claim 17. (Canceled)

Claim 18. (Canceled)

Claims 19-53. (Canceled)

54. (Previously Presented) The method of claim 16, wherein the CG is hCG.

55. (Previously Presented) The method of claim 16, wherein the female subject is a canine, a feline, an ovine, a primate, an equine, a porcine, a caprine, a camelid, an avian, a bovine, an amphibian, a fish, or a murine subject.

56. (Currently Amended) The method of claim 16, wherein the LHR<sup>exo3</sup> sequence is at least 90% identical to the amino acid sequence of the human LHR<sup>exo3</sup> domain, and the LHR<sup>exo2</sup> sequence is at least 97% identical to the amino acid sequence of the [[LHR<sup>exo1</sup>,]] LHR<sup>exo2</sup> [[, or LHR<sup>exo3</sup>]] domain.